In addition, the combined treatment of macitentan with the IK22.5 anti-RANKL antibody, made it possible to drastically reduce tumor osteoid tissue formation and the enlargement of both trabecular bone and periosteal bone secondary to inhibiting bone resorption. This evidence concerns the gene TNFSF11 and neoplasm.